Dyslipidemie

Cardiovascular diseases (CVDs) are the leading cause of death globally

Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Approach for patients with coronary artery disease (CAD): focus on LDL-C control

Why choose PRALUENT®?

The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.²

PRALUENT is available as a unique, once-monthly pen

What is PRALUENT®?

PRALUENT^®: a powerful PCSK9i that ticks all the boxes^1–4

146 for Lipid Management After ACS

2024 ESC Guidelines for the management of chronic coronary syndromes

Felicita Andreotti, Italy; Christiaan J M Vrints, Belgium

Vergoeding Praluent

Praluent is sinds 1 juni 2016 onder nadere voorwaarden vanuit de basisverzekering vergoed. Deze voorwaarden zijn vastgelegd in Bijlage 2 van de regeling zorgverzekering.